2022 Q3 Form 10-Q Financial Statement

#000095017022014868 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.044M $8.948M $7.463M
YoY Change 41.89% 39.81% 61.89%
% of Gross Profit
Research & Development $21.29M $28.92M $20.73M
YoY Change 24.37% 106.09% 30.54%
% of Gross Profit
Depreciation & Amortization $56.00K $48.00K $46.00K
YoY Change -20.0% 17.07% 53.33%
% of Gross Profit
Operating Expenses $29.34M $37.87M $28.19M
YoY Change 28.73% 85.33% 37.63%
Operating Profit -$29.34M -$37.87M -$28.19M
YoY Change 28.73% 85.33% 37.63%
Interest Expense $1.936M $147.0K $744.0K
YoY Change 125.9% -81.08% 291.58%
% of Operating Profit
Other Income/Expense, Net $2.135M $3.012M $6.899M
YoY Change 162.93% 173.57% 8313.41%
Pretax Income -$27.20M -$34.86M -$21.29M
YoY Change 23.77% 80.3% 4.37%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$27.20M -$34.86M -$21.29M
YoY Change 23.77% 80.3% 4.37%
Net Earnings / Revenue
Basic Earnings Per Share -$0.12 -$0.16 -$0.10
Diluted Earnings Per Share -$0.12 -$0.16 -$99.77K
COMMON SHARES
Basic Shares Outstanding 218.2M 216.6K 213.4K
Diluted Shares Outstanding 218.3K 216.6K 213.4K

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $673.9M $703.8M $737.7M
YoY Change -14.88% -12.75% -10.55%
Cash & Equivalents $138.7M $102.3M $106.2M
Short-Term Investments $535.3M $601.5M $631.5M
Other Short-Term Assets $5.094M $7.799M $7.841M
YoY Change 69.01% 74.4% 53.75%
Inventory
Prepaid Expenses $5.094M $7.799M $7.841M
Receivables
Other Receivables
Total Short-Term Assets $681.4M $714.3M $748.0M
YoY Change -14.46% -12.15% -9.97%
LONG-TERM ASSETS
Property, Plant & Equipment $902.0K $894.0K $747.0K
YoY Change 19.0% 16.71% -3.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $138.0K $138.0K $421.0K
YoY Change -67.22% -67.22% 5.25%
Other Assets
YoY Change
Total Long-Term Assets $5.100M $5.474M $3.768M
YoY Change 332.57% 361.16% 215.84%
TOTAL ASSETS
Total Short-Term Assets $681.4M $714.3M $748.0M
Total Long-Term Assets $5.100M $5.474M $3.768M
Total Assets $686.5M $719.7M $751.8M
YoY Change -13.95% -11.61% -9.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.995M $12.73M $9.673M
YoY Change -41.99% 183.03% 61.14%
Accrued Expenses $9.916M $7.605M $7.121M
YoY Change 21.74% 35.97% 78.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.01M $21.27M $21.44M
YoY Change 5.28% 110.84% 114.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.543M $5.385M $6.801M
YoY Change -69.95% -64.66% -56.68%
Total Long-Term Liabilities $4.543M $5.385M $6.801M
YoY Change -69.95% -64.66% -56.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.01M $21.27M $21.44M
Total Long-Term Liabilities $4.543M $5.385M $6.801M
Total Liabilities $18.55M $26.66M $28.24M
YoY Change -34.73% 5.26% 9.83%
SHAREHOLDERS EQUITY
Retained Earnings -$246.2M -$219.0M -$184.1M
YoY Change -278.79% -289.28% -290.98%
Common Stock $922.2M $919.0M $913.9M
YoY Change 1.72% 1.68% 1.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $667.9M $693.1M $723.6M
YoY Change
Total Liabilities & Shareholders Equity $686.5M $719.7M $751.8M
YoY Change -13.95% -11.61% -9.65%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$27.20M -$34.86M -$21.29M
YoY Change 23.77% 80.3% 4.37%
Depreciation, Depletion And Amortization $56.00K $48.00K $46.00K
YoY Change -20.0% 17.07% 53.33%
Cash From Operating Activities -$28.09M -$26.92M -$24.90M
YoY Change 113.66% 59.94% 69.04%
INVESTING ACTIVITIES
Capital Expenditures -$103.0K -$195.0K -$7.000K
YoY Change 255.17% 2337.5% -93.64%
Acquisitions
YoY Change
Other Investing Activities $64.31M $26.83M -$5.544M
YoY Change -170.13% -115.54% 471.55%
Cash From Investing Activities $64.20M $26.63M -$5.551M
YoY Change -170.0% -115.43% 411.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 258.0K -3.602M 4.264M
YoY Change -906.25% -6004.92% -99.32%
NET CHANGE
Cash From Operating Activities -28.09M -26.92M -24.90M
Cash From Investing Activities 64.20M 26.63M -5.551M
Cash From Financing Activities 258.0K -3.602M 4.264M
Net Change In Cash 36.37M -3.886M -26.22M
YoY Change -134.67% -97.95% -104.3%
FREE CASH FLOW
Cash From Operating Activities -$28.09M -$26.92M -$24.90M
Capital Expenditures -$103.0K -$195.0K -$7.000K
Free Cash Flow -$27.99M -$26.72M -$24.89M
YoY Change 113.35% 58.86% 70.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Stock Issued1
StockIssued1
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001811063
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
nuvb Purchase Of Property And Equipment Included In Accounts Payable
PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
nuvb Issuance Costs From Business Merger In Accounts Payable And Accrued Expenses
IssuanceCostsFromBusinessMergerInAccountsPayableAndAccruedExpenses
nuvb Operating Lease Liabilities Recognized
OperatingLeaseLiabilitiesRecognized
nuvb Reclassification Of Deferred Rent
ReclassificationOfDeferredRent
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
132423000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7799000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3642000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
601476000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
632969000
CY2022Q2 nuvb Interest Receivable On Marketable Securities Current
InterestReceivableOnMarketableSecuritiesCurrent
2668000
CY2021Q4 nuvb Interest Receivable On Marketable Securities Current
InterestReceivableOnMarketableSecuritiesCurrent
3039000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
714264000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
772073000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
894000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
786000
CY2022Q2 nuvb Lease Security Deposit Noncurrent
LeaseSecurityDepositNoncurrent
138000
CY2021Q4 nuvb Lease Security Deposit Noncurrent
LeaseSecurityDepositNoncurrent
421000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4442000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2871000
CY2022Q2 us-gaap Assets
Assets
719738000
CY2021Q4 us-gaap Assets
Assets
776151000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
12728000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3925000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
941000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
863000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7605000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12137000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
nuvb Issuance Of Common Stock For Purchase Under Espp Value
IssuanceOfCommonStockForPurchaseUnderEsppValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
218244300
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102321000
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39351
dei Entity Registrant Name
EntityRegistrantName
Nuvation Bio Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0862255
dei Entity Address Address Line1
EntityAddressAddressLine1
1500 Broadway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1401
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
332
dei Local Phone Number
LocalPhoneNumber
208-6102
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
21274000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16925000
CY2022Q2 nuvb Warrant Liability
WarrantLiability
1633000
CY2021Q4 nuvb Warrant Liability
WarrantLiability
11037000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3752000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2192000
CY2022Q2 us-gaap Liabilities
Liabilities
26659000
CY2021Q4 us-gaap Liabilities
Liabilities
30154000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
218244300
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
218244300
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
217948568
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
217948568
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
919011000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
909985000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218954000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-162803000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6978000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1185000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28922000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14034000
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-500000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
693079000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
745997000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
719738000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
776151000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49650000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29913000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8948000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6400000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16411000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11005000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
37870000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
20434000
us-gaap Operating Expenses
OperatingExpenses
66061000
us-gaap Operating Expenses
OperatingExpenses
40918000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-37870000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20434000
us-gaap Operating Income Loss
OperatingIncomeLoss
-66061000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40918000
CY2022Q2 us-gaap Interest Income Other
InterestIncomeOther
841000
CY2021Q2 us-gaap Interest Income Other
InterestIncomeOther
776000
us-gaap Interest Income Other
InterestIncomeOther
1798000
us-gaap Interest Income Other
InterestIncomeOther
1214000
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
215000
CY2021Q2 us-gaap Professional Fees
ProfessionalFees
176000
us-gaap Professional Fees
ProfessionalFees
384000
us-gaap Professional Fees
ProfessionalFees
284000
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3080000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9404000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-207000
CY2022Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-694000
CY2021Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
1000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-908000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
46000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3012000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1101000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9910000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1183000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34858000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19333000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-56151000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39735000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-19333000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-34858000
us-gaap Net Income Loss
NetIncomeLoss
-56151000
us-gaap Net Income Loss
NetIncomeLoss
-39735000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
216603
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
216603
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
204017
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
204017
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
215016
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
215016
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
186933
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
186933
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-34858000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-19333000
us-gaap Net Income Loss
NetIncomeLoss
-56151000
us-gaap Net Income Loss
NetIncomeLoss
-39735000
CY2022Q2 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-761000
CY2021Q2 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-224000
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-5793000
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-800000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35619000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19557000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61944000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40535000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
745997000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
314000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3577000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21293000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5032000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
723563000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
56000
CY2022Q2 nuvb Issuance Of Common Stock For Purchase Under The Espp
IssuanceOfCommonStockForPurchaseUnderTheEspp
292000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4787000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-34858000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-761000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
693079000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
215084000
CY2021Q1 nuvb Issuance And Exchange Of Common Stock Net Of Issuance Cost Upon Business Combination Transaction Value
IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue
606885000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-3787000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1566000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-20402000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-576000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
806344000
CY2021Q2 nuvb Issuance And Exchange Of Common Stock Net Of Issuance Cost Upon Business Combination Transaction Value
IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue
-195000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
190000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2153000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-19333000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-224000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
788935000
us-gaap Net Income Loss
NetIncomeLoss
-56151000
us-gaap Net Income Loss
NetIncomeLoss
-39735000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-3787000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
262672000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
231673000
us-gaap Share Based Compensation
ShareBasedCompensation
8364000
us-gaap Share Based Compensation
ShareBasedCompensation
3719000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
94000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
71000
nuvb Non Cash Lease Expense
NonCashLeaseExpense
67000
nuvb Non Cash Lease Expense
NonCashLeaseExpense
20000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9404000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-207000
nuvb Amortization Of Premium On Marketable Securities
AmortizationOfPremiumOnMarketableSecurities
-3507000
nuvb Amortization Of Premium On Marketable Securities
AmortizationOfPremiumOnMarketableSecurities
-1734000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-908000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
46000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
4156000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3246000
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
-371000
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
905000
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
283000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8803000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2398000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4533000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
850000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51847000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31560000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
283957000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
58108000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
202000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
118000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21083000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-173683000
us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
-624831000
nuvb Issuance Of Common Stock For Purchase Under Espp Value
IssuanceOfCommonStockForPurchaseUnderEsppValue
-292000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
370000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
190000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
662000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
625021000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30102000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
419778000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
132423000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29755000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102321000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
449533000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3917000
nuvb Operating Lease Liabilities Recognized
OperatingLeaseLiabilitiesRecognized
4074000
nuvb Reclassification Of Deferred Rent
ReclassificationOfDeferredRent
-157000
nuvb Purchase Of Property And Equipment Included In Accounts Payable
PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable
31000
us-gaap Stock Issued1
StockIssued1
3787000
nuvb Issuance Costs From Business Merger In Accounts Payable And Accrued Expenses
IssuanceCostsFromBusinessMergerInAccountsPayableAndAccruedExpenses
62000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Operations</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Nuvation Bio Inc. and subsidiaries (“Nuvation Bio”), a Delaware corporation, is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio was incorporated on March 20, 2018 (inception date) and has offices in New York and San Francisco.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On February 10, 2021, (the “Closing Date”), Nuvation Bio Inc., a Delaware corporation (“Legacy Nuvation Bio”), Panacea Acquisition Corp. (“Panacea”), and Panacea Merger Subsidiary Corp, a Delaware corporation and a direct, wholly owned subsidiary of Panacea (“Merger Sub”) consummated the transactions contemplated by an Agreement and Plan of Merger among them dated </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">October 20, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> (“Merger Agreement”).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Merger Agreement, a business combination of Panacea and Legacy Nuvation Bio was effected through the merger of Merger Sub with and into Legacy Nuvation Bio, with Legacy Nuvation Bio surviving as a wholly owned subsidiary of Panacea (the “Merger”) and, collectively with the other transactions described in the Merger Agreement. On the Closing Date, Legacy Nuvation Bio changed its name to Nuvation Bio Operating Company Inc. and Panacea changed its name to Nuvation Bio Inc. (the “Company” or “Nuvation Bio”).</span></p>
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-219000000.0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51800000
CY2022Q2 nuvb Cash And Cash Equivalents And Marketable Securities
CashAndCashEquivalentsAndMarketableSecurities
703800000
CY2022Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
1633000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
84708000
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
632969000
CY2021Q4 nuvb Total Financial Assets
TotalFinancialAssets
717677000
CY2021Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
11037000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
678136000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
57000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the year. Accordingly, actual results could differ from those estimates and those differences could be significant. Significant estimates and assumptions reflected in the accompanying consolidated financial statements include, but are not limited to, the fair value of in-process research and development acquired, warrant liabilities, leases, stock options granted and depreciation expense.</span>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of government and corporate bonds, municipal securities and exchange traded fund with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.</span></p>
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5787472
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.50
us-gaap Sale Of Stock Description Of Transaction
SaleOfStockDescriptionOfTransaction
the exercise of the Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves more than 50% of the outstanding shares of the Company’s common stock.
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
69682000
CY2022Q2 us-gaap Marketable Securities
MarketableSecurities
601476000
CY2022Q2 nuvb Total Financial Assets
TotalFinancialAssets
671158000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7035000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
671158000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
719028000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
363000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1714000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
717677000
CY2022Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
2000
CY2021Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
1000
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
9000
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
46000
CY2022Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
695000
CY2021Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
745000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-693000
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
1000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-736000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
46000
CY2022Q2 us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
0
CY2021Q2 us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
0
us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
337000
CY2022Q2 us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
1000
CY2021Q2 us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
0
us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
165000
CY2022Q2 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-1000
CY2021Q2 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
0
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-172000
CY2022Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-694000
CY2021Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
1000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-908000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
46000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
514091000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
6149000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
30337000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
875000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
544428000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
7024000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
445206000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1714000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
445206000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1714000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
481974000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
119502000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
601476000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
400
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
300
us-gaap Operating Lease Expense
OperatingLeaseExpense
700
us-gaap Operating Lease Expense
OperatingLeaseExpense
600
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
300
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
300
us-gaap Operating Lease Cost
OperatingLeaseCost
600
us-gaap Operating Lease Cost
OperatingLeaseCost
600
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
565000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1422000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1495000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1071000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
711000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5264000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
571000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4693000
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.06
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
us-gaap Market Risk Benefit Change In Fair Value Gain Loss
MarketRiskBenefitChangeInFairValueGainLoss
9400000
nuvb Fair Value Equity Level1 To Level2 Or Level3 Transfers Description
FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription
no
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1185000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1557000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-6529000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-754000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-736000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
46000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6978000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
757000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4787000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2153000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8364000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3719000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
5.47
CY2022Q2 us-gaap Market Risk Benefit Change In Fair Value Gain Loss
MarketRiskBenefitChangeInFairValueGainLoss
3100000
CY2022Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1633000
CY2021Q4 nuvb Changes In Liabilities Classified In Level3 Of Fair Value Hierarchy
ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy
406000
nuvb Change In Fair Value Of Private Warrants Liability Recognized In Earnings
ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings
-348000
CY2022Q2 nuvb Changes In Liabilities Classified In Level3 Of Fair Value Hierarchy
ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy
58000

Files In Submission

Name View Source Status
0000950170-22-014868-index-headers.html Edgar Link pending
0000950170-22-014868-index.html Edgar Link pending
0000950170-22-014868.txt Edgar Link pending
0000950170-22-014868-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nuvb-20220630.htm Edgar Link pending
nuvb-20220630.xsd Edgar Link pending
nuvb-20220630_cal.xml Edgar Link unprocessable
nuvb-20220630_def.xml Edgar Link unprocessable
nuvb-20220630_htm.xml Edgar Link completed
nuvb-20220630_lab.xml Edgar Link unprocessable
nuvb-20220630_pre.xml Edgar Link unprocessable
nuvb-ex31_1.htm Edgar Link pending
nuvb-ex31_2.htm Edgar Link pending
nuvb-ex32_1.htm Edgar Link pending
nuvb-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending